Observational studyClinical interventions in aging2025
Contezolid for the Super-Elderly: Balancing Efficacy and Safety Through Pharmacokinetic Insights.
Observational study in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Therapeutic Drug Monitoring and Pharmacokinetic Researches of Oxazolidinone Antibacterial Agents in the Elderly Patients.Clinical interventions in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Contezolid is a new oxazolidinone antibacterial agent, and its pharmacokinetic (PK) characteristics and safety in super-elderly patients remain poorly understood. Methods: Contezolid PK parameters were analyzed in enrolled super-elderly patients (≥ 80 years), with systematic assessment of steady-state profiles and adverse events. Results: Thirteen super-elderly patients (mean age: 94.9 ± 4.8 years) were included in the study. The plasma concentrations of contezolid peaked at 2-3h post administration. Both C Conclusion: Contezolid has comparable PKs in super-elderly and healthy adults. While a dosage of 400 mg q12h is sufficient for pathogens with MICs ≤ 1 mg/L, a higher dosage of 800 mg q12h is recommended for higher MICs (2-4 mg/L), with both doses demonstrating favorable safety. Clinical Trial Registration Number: ChiCTR2200056377; 4/2/2022.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.